Skip to content
Storytelling Co – Lifestyle
Author:
Surrozen, Inc.
Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
November 13, 2026
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
November 9, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
November 6, 2026
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
October 20, 2026
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
October 2, 2026
Surrozen Submits IND for SZN-8141 to Treat Diabetic Macular Edema
September 8, 2026
Surrozen to Present at Upcoming Healthcare Investor Conferences
September 2, 2026
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
July 15, 2026